title: Interleukin-10.rs1800896 and Interleukin-18.rs1946518 gene polymorphisms could not predict the outcome of hepatitis C virus infection in Egyptian patients treated with pegylated interferon plus ribavirin.
abstract: A single-nucleotide polymorphism (SNP) in the interleukin (IL)-28B gene was used as a major predictor of the response to treatment in patients with hepatitis C virus (HCV) infection. Data examining the role of IL-10 and IL-18 gene polymorphisms among HCV genotype 4 (G4)-infected Egyptians in response to pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy are limited. This study investigated the impact of SNP at IL-10.rs1800896 (at position -1082) and IL-18.rs1946518 genes (at position -607) on the response to PEG-IFN/RBV therapy in HCV-infected Egyptians. This study was carried out on 100 HCV patients treated with PEG-IFN plus RBV and 100 healthy controls. The HCV patients included 50 treatment non-responders (NR) and 50 subjects with sustained virologic response (SVR). Genomic DNA from venous blood of subjects was extracted and IL-10.rs1800896 and IL-18.rs1946518 genotypes were determined using allele-specific amplification and SYBR Green real-time PCR. Linkage disequilibrium between the two SNPs was estimated using Haploview software. The frequency of the IL-10.rs1800896 AA, AG and GG genotypes among non-responders were 16 %, 70 % and 14 % while among SVR subjects, the frequency was 34 %, 60 % and 6 %, respectively (p=0.073). On the other hand, the frequency of the IL-18.rs1946518 AA, AC and CC genotypes among non-responders was 14 %, 50 % and 36 %, respectively, while among responders, these frequencies were 28 %, 44 % and 28 %, (p = 0.220). Both markers were in linkage equilibrium (D' = 0.23; r (2) = 0.052). SNPs in the IL-10.rs1800896 and IL-18.rs1946518 genes could not predict the outcome of HCV infection in Egyptians treated with PEG-IFN/RBV.
authors.affiliation: Microbiology and Immunology Department, Faculty of Medicine, Minia University, Minia, 61511, Egypt.
authors.forename: Wedad M
authors.initials: WM
authors.lastname: Abdelraheem
authors.affiliation: Microbiology and Immunology Department, Faculty of Medicine, Minia University, Minia, 61511, Egypt.
authors.forename: Noha A
authors.initials: NA
authors.lastname: Hassuna
authors.affiliation: Microbiology and Immunology Department, Faculty of Medicine, Minia University, Minia, 61511, Egypt.
authors.forename: Sahar M
authors.initials: SM
authors.lastname: Abuloyoun
authors.affiliation: Biochemistry Department, Faculty of Medicine, Minia University, Minia, 61511, Egypt.
authors.forename: Hend M
authors.initials: HM
authors.lastname: Abdel Ghany
authors.affiliation: Microbiology and Immunology Department, Faculty of Medicine, Minia University, Minia, 61511, Egypt.
authors.forename: Hazem A
authors.initials: HA
authors.lastname: Rizk
authors.affiliation: Microbiology and Immunology Department, Faculty of Medicine, Minia University, Minia, 61511, Egypt. icpminia@yahoo.com.|Department of Microbiology, College of Pharmacy, Taif University, Al-Haweiah, PO Box 888, Taif, 21974, Kingdom of Saudi Arabia. icpminia@yahoo.com.
authors.forename: Sayed F
authors.initials: SF
authors.lastname: Abdelwahab
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004534:Egypt / Q000453:epidemiology; D005260:Female; D005786:Gene Expression Regulation; D020022:Genetic Predisposition to Disease; D005838:Genotype; D016174:Hepacivirus; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D016753:Interleukin-10 / Q000235:genetics*; D020382:Interleukin-18 / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D020382:Interleukin-18; D011994:Recombinant Proteins; D016753:Interleukin-10; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a